CD70 and neoplasm: Through the use of a comprehensive array of experimental models, including primary RCC patient samples, patient-derived tumor cell lines, in vitro functional assays, and both orthotopic and metastatic in vivo xenograft models, we demonstrate that AlloCAR70-NKT cells effectively and concurrently eliminate RCC tumor cells, modulate the immunosuppressive TME, and deplete CD70-expressing alloreactive T cells.